Peter Gimsing
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 81
- Oncology top 2%
- Cancer Treatment and Pharmacology 23
- Peptidase Inhibition and Analysis 15
- Genetics top 5%
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 25
- Amyloidosis: Diagnosis, Treatment, Outcomes 13
- Histone Deacetylase Inhibitors Research 9
- Cancer therapeutics and mechanisms 8
- Immunology top 10%
-
- Folate and B Vitamins Research 14
- Co-authors
- Lene Meldgaard KnudsenAnnette Juul VangstedIngemar TuressonErik HippeKirsten GrønbækKonstantinos DimopoulosNiels AbildgaardTobias Wirenfeldt Klausen
- Cited by
- HematologyOncologyGenetics
In The Last Decade
Peter Gimsing
110 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 97
- Hematology 2.1k
- Oncology 1.4k
- Genetics 301
- Molecular Biology 1.9k
- Immunology 324
Countries citing papers authored by Peter Gimsing
This map shows the geographic impact of Peter Gimsing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Gimsing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Gimsing more than expected).
Fields of papers citing papers by Peter Gimsing
This network shows the impact of papers produced by Peter Gimsing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Gimsing. The network helps show where Peter Gimsing may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Gimsing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 14 | |
| 2 | 2018 | 31 | |
| 3 | 2018 | 7 | |
| 4 | 2017 | 37 | |
| 5 | 2017 | 12 | |
| 6 | 2015 | 42 | |
| 7 | 2014 | 104 | |
| 8 | 2013 | 41 | |
| 9 | 2012 | 41 | |
| 10 | 2011 | 179 | |
| 11 | 2010 | 14 | |
| 12 | 2010 | 24 | |
| 13 | A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity | 2008 | 16 |
| 14 | 2007 | 6 | |
| 15 | 2004 | 29 | |
| 16 | Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 2002 | 2 |
| 17 | 1999 | 67 | |
| 18 | Presence of clonal cells in all stem cell enriched grafts in transplanted multiple myeloma. | 1997 | 1 |
| 19 | 1995 | 17 | |
| 20 | 1993 | 3 |
About Peter Gimsing
Peter Gimsing is a scholar working on Hematology, Oncology and Genetics, having authored 111 papers that have together received 3.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (25 papers), Cancer Treatment and Pharmacology (23 papers), Peptidase Inhibition and Analysis (15 papers), Folate and B Vitamins Research (14 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (13 papers), Histone Deacetylase Inhibitors Research (9 papers) and Cancer therapeutics and mechanisms (8 papers). The work is most often cited by research in Hematology (2.1k citations), Oncology (1.4k citations) and Genetics (301 citations). Peter Gimsing has collaborated with scholars based in Denmark, Sweden and Norway. Frequent co-authors include Lene Meldgaard Knudsen, Annette Juul Vangsted, Ingemar Turesson, Erik Hippe, Kirsten Grønbæk, Konstantinos Dimopoulos, Niels Abildgaard, Tobias Wirenfeldt Klausen, Hans Erik Johnsen and Ebba Nexø. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Journal of Clinical Oncology and American Journal of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.